When a new technology is evaluated and marketed, there may be uncertainty about its short or long-term consequences as it becomes available to more patients than in clinical trials.
PLEG is an umbrella term for evidence generated after the launch or licensure of a health technology within its approved or intended indication.
Its role is not to replace but to complement evidence generation already undertaken for marketing authorisation or HTA appraisal, addressing remaining uncertainties but also potentially covering wider questions of disease management and healthcare delivery.
PLEG contributes to the overall and accumulating evidence about a health technology during the life-cycle.
EUnetHTA is currently conducting two types of collaboration on PLEG:
Any PLEG pilot must fulfil EUnetHTA Selection-prioritisation criteria for PLEG.
Moreover, the pilots follow general EUneHTA PLEG guidance and EUnetHTA registry quality standards (REQueST tool).
For further information on EUnetHTA PLEG pilots, please contact email@example.com
1) PRODUCT-SPECIFIC PLEG PILOTS ARISING FROM HTA
Product-specific PLEG pilots can arise from evidence gaps identified either in national assessments of EUnetHTA partners, or directly in EUnetHTA assessments.
The pilots consist in agreeing, among participating agencies, on the common requirements for PLEG (common minimum data set, quality requirements) for a specific product, to inform its re-assessment. The jointly defined requirements are used as a basis to set up PLEG at the national level.
Whenever possible, pilots also have a second phase, which consists in compiling and analysing the generated data from different jurisdictions.
EUnetHTA JA3 product-specific PLEG pilots
* First reports (first phase): common evidence gaps report ; minimum data set report. Second report (second phase) : final report with compiled data.
** Agencies participating only in the first phase.
2) REGISTRY-SPECIFIC PLEG PILOTS
Registry-specific pilots consist of assessing the suitability of existing data sources (registries) for PLEG purposes, in terms of variables collected and the quality of data collection. Since 2019, the latter is being assessed with the help of the REQueST tool.
The pilot report contains non-binding recommendations from participating agencies on the discussed aspects (variables collected, data quality).
EUnetHTA JA3 registry-specific PLEG pilots
* Pilot performed in collaboration with the EMA.
The following report has been developed to outline recommendations for PLEG, going forward, based on JA3 learnings:
Recommendations and tools for post- launch evidence generation
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.